Advitech has announced statistically significant efficacy results and important clinical trends with regard to Dermylex in the treatment of mild to moderate psoriasis. When compared with the placebo group, the Dermylex-treated group showed a reduction in psoriasis area and severity index (PASI), itching sensation and body surface area (BSA).
The Journal of Cutaneous Medicine and Surgery will publish this month the open clinical study results performed in early 2004 with Dermylex, while an article on the results of the double-lind, placebo-controlled clinical study has received provisional acceptance pending the completion of satisfactory reviews by the assessment committee and should be published in the coming months.
Dermylex is Advitech's orally administered product for mild to moderate plaque psoriasis made from a bioactive ingredient with proven clinical efficacy.
